Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Enhanced procoagulant activity of select hemophilia B causing factor IX variants with emicizumab

10 Jul 2024

Abstract excerpt

ABSTRACT: Emicizumab improves the procoagulant activity of select loss-of-function factor IX (FIX) variants with likely dysfunctional assembly of the intrinsic Xase complex, resulting in hemophilia B (HB). FVIII mimetics may represent an alternative nonfactor therapy for select patients with HB.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood Coagulation and Thrombosis Mechanisms
Share to Coagulation, Bradykinin, Polyphosphates, and Angioedema
Share to Hemophilia Treatment and Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38985830
DOI: 10.1182/blood.2023021944

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Enhanced procoagulant activity of select hemophilia B causing factor IX variants with emicizumabPMID 38985830Read ↗

Coagulation factor VIII: biological basis of emerging hemophilia A therapiesSemantic proximity Read ↗

A bispecific antibody NXT007 exerts a hemostatic activity in hemophilia A monkeys enough to keep a non-hemophiliac stateSemantic proximity Read ↗

Novel molecules for the correction of factor Xa generation and phenotype in hemophilia.Semantic proximity Read ↗

Emerging genetic and pharmacologic therapies for controlling hemostasis: beyond recombinant clotting factors.Semantic proximity Read ↗

Recombinant Factor IX for Clinical and Research UseSemantic proximity Read ↗

Engineered factor IX variants bypass FVIII and correct hemophilia A phenotype in mice.Semantic proximity Read ↗

Prophylactic Therapy with Emicizumab in Patients with Hemophilia A: Benefits and ChallengesSemantic proximity Read ↗

Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia BSemantic proximity Read ↗

A factor IX variant that functions independently of factor VIII mitigates the hemophilia A phenotype in patient plasma.Semantic proximity Read ↗

Next generation FIX muteins with FVIII-independent activity for alternative treatment of hemophilia A.Semantic proximity Read ↗

Mutating factor VIII: lessons from structure to function.Semantic proximity Read ↗

Factor IX variants improve gene therapy efficacy for hemophilia BSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.